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Individuals who suﬀ   er traumatic intracranial hemor-
rhages (ICHs), the most common cause of morbidity and 
mortality in adults younger than 40 years of age, not only 
incur neurologic deﬁ  cits but also are at increased risk for 
complications. Th  warting such complications is para-
mount to preserving quality of life and improving the 
likeli  hood for survival. As such, preventing venous 
thrombo  embolism (VTE), the single most preventable 
cause of morbidity and mortality in neurosurgical 
patients, is of utmost priority. Th  e decision to initiate 
VTE prophylaxis in the setting of a traumatic ICH must 
be carefully considered. Failure to use VTE prophylaxis 
may result in serious or fatal pulmonary embolism (PE), 
whereas the use of anticoagulants may potentiate further 
intracranial bleeding, thereby worsening neurologic 
function and possibly precipitating death. Th   e paucity of 
clinical trials addressing the safety and eﬃ   cacy  of 
chemical thromboprophylaxis in this patient population 
leaves clinicians guessing in regard to the appropriate 
dose, timing, and duration for thromboprophylaxis in the 
presence of an ICH. Th   us, it is left to the physician at the 
bedside to weigh the risks versus beneﬁ   ts of anti-
coagulation in the face of the existing potential for a 
serious PE or the progression of a head bleed. Th  e  pivotal 
question is: how much preventive beneﬁ   t must be 
provided in order to outweigh the potential bleeding risk?
In the previous issue of Critical Care, Scales and 
colleagues [1] attempted to address this question and 
illustrate the diﬃ   culty of making this choice in traumatic 
ICH patients, particularly within 24 hours of the injury. 
In a decision analysis examining the risks of ICH progres-
sion versus the risks of VTE, the authors concluded that 
there was no clear beneﬁ  t to providing (expected value = 
0.89) or withholding (expected value = 0.90) thrombo-
prophy  laxis with low-molecular-weight heparin (LMWH). 
Although their results were incon  clusive, they erred on 
the side of caution and recom  mended withholding 
anticoagulant prophylaxis, particularly early after the 
initial insult when bleeding progression is perceived to be 
highest. Because the administration of blood thinners 
could exacerbate bleeding in an enclosed space and result 
in the worsening of already poor neurologic function, 
these recommendations are reasonable.
On the other hand, the consequences of initiating VTE 
prophylaxis in this population may not be as devastating 
as one would think. In the general trauma population, 
thromboprophylaxis is the standard of care because of 
the astonishingly high incidence of deep venous throm-
bosis (DVT) development, which consistently exceeds 
50% [2,3]. Th  e ability of DVT prophylaxis to achieve a 
substantial degree of risk reduction (approximately 50%), 
coupled with an overall low major bleeding rate (less than 
2%) [4], clearly demonstrates that the beneﬁ  ts of its use 
outweigh the risks of bleeding. Except for the diﬀ  erence 
in location of traumatic injury, those suﬀ  ering  from 
traumatic ICHs are no diﬀ  erent than the general trauma 
population. To think that their risk of bleeding is 
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intracranial hemorrhage (ICH) are at high risk for 
developing venous thromboembolism (VTE). The 
use of thromboprophylaxis is eff  ective at decreasing 
the rate of VTE, but at the potential expense of an 
increased risk of ICH progression. Physicians must 
carefully consider both the benefi  ts and risks of VTE 
prophylaxis before prescribing chemical anticoagulants 
to these patients. To help clarify this diffi   cult choice, 
Scales and colleagues performed a decision analysis to 
determine whether the benefi  ts of thromboprophylaxis 
outweigh the potential risk of worsening ICH. There 
is increasing evidence that bleeding risks are not 
as prominent as previously thought. Although the 
results were largely inconclusive, the present study has 
identifi  ed areas for future research.
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not seem biologically plausible. Additionally, prospective 
observational evidence has shown that progression of 
bleeding after traumatic head injuries is highest during 
the ﬁ  rst 24-hour period, even in the absence of thrombo-
prophylaxis [5]. Despite initiation of DVT prophylaxis at 
24 hours, the risk of bleeding does not signiﬁ  cantly 
increase (4%) unless a surgical procedure is required. 
Th  us, in the appropriate patient suﬀ  ering from an ICH, 
the advantages of thromboprophylaxis outweigh poten-
tial disadvantages.
In the same vein, emerging data suggest that pharma-
co  logic prophylaxis with LMWH does not substantially 
increase anti-Xa levels when used for DVT prophylaxis, 
even for patients with severe renal impairment. Th  e 
DIRECT (Dalteparin’s Inﬂ  uence on the Renally Compro-
mised: Anti-Xa) study [6] demonstrated that in 99% of 
patients with a creatinine clearance of less than 30 mL/
minute, trough anti-Xa levels were either undetectable 
(less than 0.10 IU/mL) or minimal (0.10 to 0.20 IU/mL). 
Additionally, no associa  tion between major bleeding and 
anti-Xa levels was found. Th   erefore, if LMWH does not 
accumulate even in the face of severe renal insuﬃ   ciency, 
the likelihood that it will accumulate and precipitate bleed-
ing seems low in a typical patient with traumatic ICH.
Growing evidence suggests that our current thrombo-
prophylaxis regimens are relatively safe and possibly even 
suboptimal [7,8]. Taking the risk-beneﬁ   t equation one 
step further, it is likely that the early administration of 
DVT prophylaxis in this patient population may be less 
hazardous than the alternative of full-dose anticoagu-
lation or an inferior vena cava (IVC) ﬁ  lter when VTE 
actually develops. Th   e potential long-term complications 
associated with an IVC ﬁ  lter, namely IVC thrombosis, 
migration of the ﬁ  lter [9], and increased risk for DVT 
[10], must be contemplated before its placement. Despite 
these considerations, the lack of concrete evidence from 
a randomized controlled trial leaves physicians skeptical 
about the safety of thromboprophylaxis in the setting of a 
traumatic ICH. Th  is uncertainty is mirrored in the 
decision analysis by Scales and colleagues [1], in which 
the estimated risk of ICH progression, even without 
exposure to anticoagulants, ranged widely from 0.001 to 
0.990. Hence, at the very least, the ﬁ  ndings of this study 
illustrate that much research is still needed to clarify the 
appropriate timing, dose, and patient characteristics to 
safely administer VTE prophylaxis in this population. 
Furthermore, this study has identiﬁ  ed the need for a risk 
stratiﬁ  cation tool to select those patients who are at low 
risk for ICH progression and would be ideal candidates 
for DVT prophylaxis at 24 hours. In the meantime, while 
we await more information, it seems that the decision to 
administer thromboprophylaxis should be cautiously 
considered on an individual basis.
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